Bank of America’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-140,000
| Closed | -$11.5M | – | 8172 |
|
|
2024
Q2 | $11.5M | Buy |
+140,000
| New | +$11.7M | ﹤0.01% | 2804 |
|
|
2022
Q3 | – | Sell |
-28,500
| Closed | -$2.36M | – | 7838 |
|
|
2022
Q2 | $2.36M | Buy |
28,500
+27,700
| +3,463% | +$2.21M | ﹤0.01% | 4156 |
|
|
2022
Q1 | $62K | Hold |
800
| – | – | ﹤0.01% | 7086 |
|
|
2021
Q4 | $71K | Buy |
+800
| New | +$66K | ﹤0.01% | 7045 |
|
|
2021
Q3 | – | Sell |
-42,800
| Closed | -$3.57M | – | 8109 |
|
|
2021
Q2 | $3.57M | Sell |
42,800
-92,200
| -68% | -$7.31M | ﹤0.01% | 3830 |
|
|
2021
Q1 | $10.2M | Buy |
135,000
+85,000
| +170% | +$6.94M | ﹤0.01% | 2700 |
|
|
2020
Q4 | $4.38M | Sell |
50,000
-55,000
| -52% | -$4.36M | ﹤0.01% | 3253 |
|
|
2020
Q3 | $7.99M | Hold |
105,000
| – | – | ﹤0.01% | 2466 |
|
|
2020
Q2 | $13M | Buy |
105,000
+5,000
| +5% | +$497K | ﹤0.01% | 1994 |
|
|
2020
Q1 | $8.45M | Hold |
100,000
| – | – | ﹤0.01% | 2205 |
|
|
2019
Q4 | $8.46M | Sell |
100,000
-86,200
| -46% | -$6.51M | ﹤0.01% | 2720 |
|
|
2019
Q3 | $12.6M | Buy |
186,200
+106,500
| +134% | +$8.2M | ﹤0.01% | 2278 |
|
|
2019
Q2 | $6.83M | Buy |
+79,700
| New | +$6.82M | ﹤0.01% | 2923 |
|
|
2019
Q1 | – | Sell |
-77,300
| Closed | -$6.58M | – | 7109 |
|
|
2018
Q4 | $6.58M | Buy |
77,300
+1,700
| +2% | +$162K | ﹤0.01% | 2719 |
|
|
2018
Q3 | $7.33M | Hold |
75,600
| – | – | ﹤0.01% | 2819 |
|
|
2018
Q2 | $7.12M | Hold |
75,600
| – | – | ﹤0.01% | 2793 |
|
|
2018
Q1 | $6.13M | Buy |
75,600
+1,500
| +2% | +$129K | ﹤0.01% | 2894 |
|
|
2017
Q4 | $6.61M | Buy |
74,100
+52,700
| +246% | +$4.58M | ﹤0.01% | 2872 |
|
|
2017
Q3 | $1.99M | Buy |
+21,400
| New | +$1.89M | ﹤0.01% | 3987 |
|
|
2017
Q1 | – | Sell |
-14,000
| Closed | -$1.16M | – | 6973 |
|
|
2016
Q4 | $1.16M | Sell |
14,000
-28,500
| -67% | -$2.45M | ﹤0.01% | 4221 |
|
|
2016
Q3 | $3.93M | Sell |
42,500
-2,500
| -6% | -$235K | ﹤0.01% | 3060 |
|
|
2016
Q2 | $3.5M | Sell |
45,000
-63,500
| -59% | -$5.4M | ﹤0.01% | 3121 |
|
|
2016
Q1 | $8.95M | Buy |
108,500
+62,400
| +135% | +$5.08M | ﹤0.01% | 2249 |
|
|
2015
Q4 | $4.83M | Buy |
46,100
+16,100
| +54% | +$1.68M | ﹤0.01% | 2979 |
|
|
2015
Q3 | $3.16M | Sell |
30,000
-20,000
| -40% | -$2.67M | ﹤0.01% | 3332 |
|
|
2015
Q2 | $6.84M | Hold |
50,000
| – | – | ﹤0.01% | 2284 |
|
|
2015
Q1 | $6.23M | Buy |
50,000
+48,800
| +4,067% | +$5.17M | ﹤0.01% | 2268 |
|
|
2014
Q4 | $108K | Sell |
1,200
-1,000
| -45% | -$83.2K | ﹤0.01% | 5821 |
|
|
2014
Q3 | $159K | Buy |
2,200
+700
| +47% | +$46K | ﹤0.01% | 5595 |
|
|
2014
Q2 | $93K | Buy |
1,500
+100
| +7% | +$6.04K | ﹤0.01% | 6197 |
|
|
2014
Q1 | $95K | Sell |
1,400
-3,100
| -69% | -$228K | ﹤0.01% | 6032 |
|
|
2013
Q4 | $317K | Buy |
4,500
+1,700
| +61% | +$115K | ﹤0.01% | 5169 |
|
|
2013
Q3 | $202K | Sell |
2,800
-83,600
| -97% | -$5.56M | ﹤0.01% | 5435 |
|
|
2013
Q2 | $4.82M | Buy |
+86,400
| New | +$5.38M | ﹤0.01% | 2320 |
|
Other funds holding BMRN
VCM
VPM
Bank of America's BMRN Position: Q1 2026 in Review
Bank of America increased its BioMarin Pharmaceuticals (BMRN) stake by 8.4% in Q1 2026, buying an estimated $4.22M and bringing the position to 936,951 shares worth $52.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1550.
Bank of America first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $342M in Q1 2023. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Bank of America held 936,951 shares of BioMarin Pharmaceuticals worth $52.9M as of Q1 2026.
- Bank of America bought 72,439 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $4.22M.
- BioMarin Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1550 holding.
- Bank of America first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Bank of America's BioMarin Pharmaceuticals position peaked at $342M in Q1 2023.
- 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.